
Stephen Fawell

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3335542/publications.pdf Version: 2024-02-01



STEDHEN FAMELL

#	Article	IF	CITATIONS
1	BRD4 Inhibition Is Synthetic Lethal with PARP Inhibitors through the Induction of Homologous Recombination Deficiency. Cancer Cell, 2018, 33, 401-416.e8.	16.8	215
2	Challenges and Opportunities in Cancer Drug Resistance. Chemical Reviews, 2021, 121, 3297-3351.	47.7	203
3	EED-Targeted PROTACs Degrade EED, EZH2, and SUZ12 in the PRC2 Complex. Cell Chemical Biology, 2020, 27, 41-46.e17.	5.2	131
4	Development of a Novel B-Cell Lymphoma 6 (BCL6) PROTAC To Provide Insight into Small Molecule Targeting of BCL6. ACS Chemical Biology, 2018, 13, 3131-3141.	3.4	110
5	Drug mechanismâ€ofâ€action discovery through the integration of pharmacological and <scp>CRISPR</scp> screens. Molecular Systems Biology, 2020, 16, e9405.	7.2	63
6	Discovery of AZD9833, a Potent and Orally Bioavailable Selective Estrogen Receptor Degrader and Antagonist. Journal of Medicinal Chemistry, 2020, 63, 14530-14559.	6.4	59
7	Discovery of 5-{4-[(7-Ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl]piperazin-1-yl}- <i>N</i> -methylpyridine-2-carboxamic (AZD5305): A PARP1–DNA Trapper with High Selectivity for PARP1 over PARP2 and Other PARPs. Journal of Medicinal Chemistry. 2021. 64. 14498-14512.	de 6.4	50
8	Discovery of (2 <i>R</i>)- <i>N</i> -[3-[2-[(3-Methoxy-1-methyl-pyrazol-4-yl)amino]pyrimidin-4-yl]-1 <i>H</i> -indol-7-yl]-2-(4-metl (AZD4205) as a Potent and Selective Janus Kinase 1 Inhibitor. Journal of Medicinal Chemistry, 2020, 63, 4517-4527.	nylpiperaz	:in , 1-yl)prope
9	<i>STAT3</i> Antisense Oligonucleotide Remodels the Suppressive Tumor Microenvironment to Enhance Immune Activation in Combination with Anti–PD-L1. Clinical Cancer Research, 2020, 26, 6335-6349.	7.0	26
10	Direct targeting of FOXP3 in Tregs with AZD8701, a novel antisense oligonucleotide to relieve immunosuppression in cancer. , 2022, 10, e003892.		26
11	Effective combination therapies in preclinical endocrine resistant breast cancer models harboring ER mutations. Oncotarget, 2016, 7, 54120-54136.	1.8	23
12	Comparative analysis of primary <i>versus</i> relapse/refractory DLBCL identifies shifts in mutation spectrum. Oncotarget, 2017, 8, 99237-99244.	1.8	23
13	Discovery and pharmacological characterization of AZD3229, a potent KIT/PDGFRα inhibitor for treatment of gastrointestinal stromal tumors. Science Translational Medicine, 2020, 12, .	12.4	16
14	Optimization of a series of potent, selective and orally bioavailable SYK inhibitors. Bioorganic and Medicinal Chemistry Letters, 2020, 30, 127433.	2.2	4